Cargando…

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis

OBJECTIVE: Macrophage activation syndrome (MAS) is a life-threatening, potentially fatal condition associated with systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) is a key cytokine in the pathogenesis of sJIA MAS. Many cases of MAS are medically refractory to traditional doses of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kostik, Mikhail M., Isupova, Eugenia A., Belozerov, Konstantin, Likhacheva, Tatyana S., Suspitsin, Evgeny N., Raupov, Rinat, Masalova, Vera V., Chikova, Irina A., Dubko, Margarita F., Kalashnikova, Olga V., Chasnyk, Vyacheslav G., Cron, Randy Q.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366524/ https://www.ncbi.nlm.nih.gov/pubmed/35967555 http://dx.doi.org/10.3389/fped.2022.894846

Ejemplares similares

Identification of the best cut-off points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis
por: Kostik, Mikhail M, et al.
Publicado: (2014)

Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study
por: Kostik, Mikhail, et al.
Publicado: (2023)

The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
por: Kostik, Mikhail M., et al.
Publicado: (2022)

Anemia in children with JIA: is it really driven by hepcidin level, or by a set of factors of a chronic disease
por: Egorov, Andrey, et al.
Publicado: (2014)

Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis
por: Kostik, Mikhail M, et al.
Publicado: (2015)

IFIH1 and DDX58 gene variants in pediatric rheumatic diseases
por: Raupov, Rinat, et al.
Publicado: (2023)

Uveitis Is a Risk Factor for Juvenile Idiopathic Arthritis' Significant Flare in Patients Treated With Biologics
por: Kostik, Mikhail M., et al.
Publicado: (2022)

PReS-FINAL-2233: Retrospective analysis of different treatment strategies in chronic non-bacterial osteomyelitis
por: Kostik, MM, et al.
Publicado: (2013)

PReS-FINAL-2154: The early predictors of fatal outcome of macrophage activation syndrome in pediatric rheumatic diseases
por: Kostik, MM, et al.
Publicado: (2013)

Comparison of different treatment approaches in chronic non-bacterial osteomyelitis.
por: Kostik, M, et al.
Publicado: (2015)

Simultaneous Onset of Pediatric Systemic Lupus Erythematosus in Twin Brothers: Case Report
por: Raupov, Rinat K., et al.
Publicado: (2022)

Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study
por: Alexeeva, Ekaterina, et al.
Publicado: (2023)

Determination of Risk Factors for Severe Life-Threatening Course of Multisystem Inflammatory Syndrome Associated with COVID-19 in Children
por: Avrusin, Ilia S., et al.
Publicado: (2023)

Juvenile Dermatomyositis and Infantile Cerebral Palsy: Aicardi-Gouteres Syndrome, Type 5, with a Novel Mutation in SAMHD1—A Case Report
por: Sorokina, Lubov S., et al.
Publicado: (2023)

P03-006 - Pamidronate rapidly decreases CRP and TNFΑ in CNO
por: Kostik, MM, et al.
Publicado: (2013)

COVID-19 Associated Vasculitis Confirmed by the Tissues RT-PCR: A Case Series Report
por: Belozerov, Konstantin E., et al.
Publicado: (2023)

Distinguishing Between Multisystem Inflammatory Syndrome, Associated With COVID-19 in Children and the Kawasaki Disease: Development of Preliminary Criteria Based on the Data of the Retrospective Multicenter Cohort Study
por: Kostik, Mikhail M., et al.
Publicado: (2021)

Hip Involvement in Juvenile Idiopathic Arthritis: A Roadmap From Arthritis to Total Hip Arthroplasty or How Can We Prevent Hip Damage?
por: Sorokina, Lubov S., et al.
Publicado: (2021)

Juvenile idiopathic arthritis with systemic onset with inflammatory bone lesions: two case reports of patients successfully treated with canakinumab and experience gained from literature
por: Alexeeva, Ekaterina I., et al.
Publicado: (2023)

Heart Involvement in Multisystem Inflammatory Syndrome, Associated With COVID-19 in Children: The Retrospective Multicenter Cohort Data
por: Kostik, Mikhail M., et al.
Publicado: (2022)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Differences in disease activity in cryopyrin-associated periodic syndrome in mutation-positive and mutation-negative patients
por: Kostik, M, et al.
Publicado: (2015)

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
por: Quartier, Pierre, et al.
Publicado: (2020)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Case report: Sulfasalazine-induced hypersensitivity
por: Kuchinskaya, Ekaterina M., et al.
Publicado: (2023)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Treatment of juvenile idiopathic arthritis: a revolution in care
por: Stoll, Matthew L, et al.
Publicado: (2014)

Quiet Areas and the Need for Quietness in Amsterdam
por: Booi, Hester, et al.
Publicado: (2012)

The temporomandibular joint in juvenile idiopathic arthritis: frequently used and frequently arthritic
por: Ringold, Sarah, et al.
Publicado: (2009)

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
por: Brachat, Arndt H., et al.
Publicado: (2017)

Association of the polymorphisms P53 gene with juvenile idiopathic arthritis in children Russian Fedration
por: Kozhevnikov, Alexey N, et al.
Publicado: (2011)

Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome
por: Gorodetskiy, Vadim R., et al.
Publicado: (2018)

Experience of the concentration of methotrexate evaluation in children with juvenile idiopathic arthritis
por: Rokhlina, FV, et al.
Publicado: (2011)

PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis
por: Xiong, Y, et al.
Publicado: (2013)

Recent progress in the treatment of non-systemic juvenile idiopathic arthritis
por: Bridges, John M, et al.
Publicado: (2021)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

The quiet American /
por: Greene, Graham, 1904-1991
Publicado: (1955)

Cannot write session to /tmp/vufind_sessions/sess_a6bcjubpttnocguovs0g4ke723